RESUMEN
From the French Invasion of Russia in 1812, to Glastonbury festival in 2007, trench foot has been reported, yet the exact nature of the condition remains unclear. This review explores the pathogenesis and treatment of trench foot. Trench foot is considered to be a nonfreezing cold injury often complicated by infection, in which exposure to cold temperatures just above freezing, combined with moisture, results in a peripheral vasoneuropathy. The presence of physical trauma, bacterial or fungal infections, malnutrition, venous hypertension and lymphoedema mean that some individuals are at greater risk of trench foot. Trench foot may be prevented by warming the feet, changing socks, staying active, rubbing the skin with oil and regularly inspecting the feet. Avoiding risk factors may help prevent the condition. The management of trench foot is less clear. Vasodilators such as iloprost and nicotinyl tartrate or sympathectomy may help. Trench foot may lead to necrosis, cellulitis, sepsis and amputation. It remains a poorly understood condition.
Asunto(s)
Frío/efectos adversos , Pie de Inmersión , Vasodilatadores/uso terapéutico , Celulitis (Flemón)/etiología , Pie/patología , Humanos , Pie de Inmersión/etiología , Pie de Inmersión/prevención & control , Pie de Inmersión/terapia , Factores de Riesgo , Agua/efectos adversosAsunto(s)
Ciclosporina/administración & dosificación , Fármacos Dermatológicos/administración & dosificación , Inmunosupresores/administración & dosificación , Fototerapia/métodos , Enfermedades de la Piel/tratamiento farmacológico , Administración Oral , Desmineralización Ósea Patológica/inducido químicamente , Niño , Contraindicaciones de los Medicamentos , Consejo , Ciclosporina/efectos adversos , Ciclosporina/farmacología , Fármacos Dermatológicos/efectos adversos , Fármacos Dermatológicos/farmacología , Vías de Administración de Medicamentos , Esquema de Medicación , Erupciones por Medicamentos/etiología , Interacciones Farmacológicas , Quimioterapia Combinada , Femenino , Humanos , Hiperlipidemias/inducido químicamente , Hipertensión/inducido químicamente , Inmunosupresores/efectos adversos , Inmunosupresores/farmacología , Anamnesis , Uso Fuera de lo Indicado , Infecciones Oportunistas/inducido químicamente , Examen Físico , Embarazo , VacunaciónRESUMEN
BACKGROUND: Hyperhidrosis is uncontrollable excessive sweating, which occurs at rest, regardless of temperature. The symptoms of hyperhidrosis can significantly affect quality of life. OBJECTIVES: To undertake a systematic review of the clinical effectiveness and safety of treatments available in secondary care for the management of primary hyperhidrosis. METHODS: Fifteen databases (including trial registers) were searched to July 2016 to identify studies of secondary-care treatments for primary hyperhidrosis. For each intervention randomized controlled trials (RCTs) were included where available; where RCT evidence was lacking, nonrandomized trials or large prospective case series were included. Outcomes of interest included disease severity, sweat rate, quality of life, patient satisfaction and adverse events. Trial quality was assessed using a modified version of the Cochrane Risk of Bias tool. Results were pooled in pairwise meta-analyses where appropriate, otherwise a narrative synthesis was presented. RESULTS: Fifty studies were included in the review: 32 RCTs, 17 nonrandomized trials and one case series. The studies varied in terms of population, intervention and methods of outcome assessment. Most studies were small, at high risk of bias and poorly reported. The interventions assessed were iontophoresis, botulinum toxin (BTX) injections, anticholinergic medications, curettage and newer energy-based technologies that damage the sweat gland. CONCLUSIONS: The evidence for the effectiveness and safety of treatments for primary hyperhidrosis is limited overall, and few firm conclusions can be drawn. However, there is moderate-quality evidence to support the use of BTX for axillary hyperhidrosis. A trial comparing BTX with iontophoresis for palmar hyperhidrosis is warranted.
Asunto(s)
Hiperhidrosis/terapia , Satisfacción del Paciente , Atención Secundaria de Salud/métodos , Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas Tipo A/efectos adversos , Antagonistas Colinérgicos/administración & dosificación , Antagonistas Colinérgicos/efectos adversos , Legrado/efectos adversos , Legrado/métodos , Humanos , Hiperhidrosis/diagnóstico , Hiperhidrosis/patología , Iontoforesis/efectos adversos , Iontoforesis/métodos , Terapia por Luz de Baja Intensidad/efectos adversos , Terapia por Luz de Baja Intensidad/métodos , Ablación por Radiofrecuencia/efectos adversos , Ablación por Radiofrecuencia/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto , Índice de Severidad de la Enfermedad , Glándulas Sudoríparas/patología , Glándulas Sudoríparas/efectos de la radiación , Resultado del TratamientoAsunto(s)
Antipruriginosos/administración & dosificación , Prurito/terapia , Administración Cutánea , Adulto , Anciano , Terapias Complementarias , Erupciones por Medicamentos/complicaciones , Infestaciones Ectoparasitarias/complicaciones , Emociones , Enfermedades del Sistema Endocrino/complicaciones , Predicción , Enfermedades Hematológicas/complicaciones , Humanos , Infecciones/complicaciones , Deficiencias de Hierro , Sobrecarga de Hierro/complicaciones , Hepatopatías/complicaciones , Trastornos Mentales/complicaciones , Neoplasias/complicaciones , Enfermedades del Sistema Nervioso/complicaciones , Fototerapia/métodos , Atención Primaria de Salud , Prurito/diagnóstico , Prurito/etiología , Uremia/complicacionesRESUMEN
Pityriasis rubra pilaris (PRP) represents a group of rare chronic inflammatory skin disorders in which around one in 20 affected individuals show autosomal dominant inheritance. In such cases there may be gain-of-function mutations in CARD14, encoding caspase recruitment domain-containing protein 14 (CARD14), which activates the noncanonical nuclear factor (NF)-κB pathway, thereby promoting cutaneous inflammation. Here we report a mother and son with PRP due to a new missense mutation in CARD14 and describe the beneficial clinical effects of ustekinumab, a monoclonal antibody against interleukins 12 and 23, in both patients. A 49-year-old woman and her 20-year-old son had lifelong, generalized, patchy erythematous scale with a few islands of sparing, as well as minor nail ridging and mild palmoplantar keratoderma, features consistent with generalized PRP. Topical steroids, phototherapy and oral retinoids proved ineffective. Following informed consent, Sanger sequencing of CARD14 in both individuals revealed a new heterozygous single-nucleotide transversion in exon 4, c.356T>G, resulting in the missense mutation p.Met119Arg. Ustekinumab, at a dose of 45 mg every 12 weeks, brought about a significant physical and emotional improvement in both the mother and son within a few days of the initial dose, which was sustained on maintenance dosing. This report highlights the therapeutic potential of biologics that downregulate NF-κB signalling in familial PRP with mutations in CARD14.